Overview Dividends

(STE) STERIS - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: IE00BFY8C754

Sterilizers, Disinfectants, Washers, Tables, Services

STE EPS (Earnings per Share)

EPS Growth (3y CAGR): 7.59%
EPS Trend (3y Corr): 62.3%

Last SUE: 1.35σ

STE Revenue

Revenue Growth (3y CAGR): 6.88%
Revenue Trend (3y Corr): 63.7%

Last SUE: 0.26σ

Risk via 10d forecast
Volatility	21.4%
Value at Risk 5%th	33.2%
Relative Tail Risk	-5.63%

Reward TTM
Sharpe Ratio	0.62
Alpha	8.28

Character TTM
Hurst Exponent	0.465
Beta	0.502
Beta Downside	0.492

Drawdowns 3y
Max DD	19.93%
Mean DD	6.83%
Median DD	5.98%

Description: STE STERIS October 14, 2025

STERIS plc (NYSE: STE) is a U.S.–based provider of infection-prevention products and services, organized into three operating segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment supplies cleaning chemistries, endoscope reprocessing systems, sterilizers, surgical tables, lights, and related capital-equipment services; the AST segment offers contract sterilization and testing for medical-device and pharmaceutical manufacturers; and the Life Sciences segment manufactures consumables (e.g., detergents, disinfectants, vaporized-hydrogen-peroxide systems) and high-purity water/steam generators, together with installation and maintenance contracts.

In fiscal 2023 STE reported revenue of roughly $4.1 billion, with an adjusted operating margin of about 12 % and free-cash-flow conversion near 15 %. Growth has been driven by two secular trends: (1) rising global demand for infection-control solutions amid heightened awareness of hospital-acquired infections, and (2) expanding outsourcing of sterilization by pharmaceutical and med-device firms seeking to reduce capital-expenditure cycles. The 2022 acquisition of Integrated Healthcare Solutions added endoscope-reprocessing capabilities, which analysts estimate contributed ~3-4 % of FY2023 revenue.

Key macro drivers include aging populations (increasing procedure volumes), tighter regulatory standards for sterility assurance, and supply-chain pressures on high-purity water and steam equipment-factors that can amplify STE’s pricing power but also introduce execution risk. Assuming continued FY-24 revenue growth of 5-6 % and stable margins, the company’s valuation could be sensitive to changes in contract-sterilization demand and capital-equipment replacement cycles.

For a deeper quantitative assessment, the ValueRay platform provides granular cash-flow and valuation models that let you test these assumptions and explore scenario outcomes.

STE Stock Overview

Market Cap in USD	25,561m
Sub-Industry	Health Care Equipment
IPO / Inception	1992-06-01
Return 12m vs S&P 500	4.40%
Analyst Rating	3.80 of 5

STE Dividends

Metric	Value
Dividend Yield	1.16%
Yield on Cost 5y	1.60%
Yield CAGR 5y	9.08%
Payout Consistency	96.9%
Payout Ratio	24.3%

STE Growth Ratios

Metric	Value
CAGR 3y	14.35%
CAGR/Max DD Calmar Ratio	0.72
CAGR/Mean DD Pain Ratio	2.10
Current Volume	532.9k
Average Volume	706.8k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (688.5m TTM) > 0 and > 6% of Revenue (6% = 342.2m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 21.35% (prev 22.55%; Δ -1.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 1.30b > Net Income 688.5m (YES >=105%, WARN >=100%)

Net Debt (1.74b) to EBITDA (1.47b) ratio: 1.19 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (98.8m) change vs 12m ago -0.41% (target <= -2.0% for YES)

Gross Margin 44.29% (prev 43.00%; Δ 1.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 55.22% (prev 49.04%; Δ 6.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 14.60 (EBITDA TTM 1.47b / Interest Expense TTM 67.0m) >= 6 (WARN >= 3)

Altman Z'' 4.43

(A) 0.12 = (Total Current Assets 2.11b - Total Current Liabilities 888.9m) / Total Assets 10.41b

(B) 0.26 = Retained Earnings (Balance) 2.73b / Total Assets 10.41b

(D) 2.07 = Book Value of Equity 7.01b / Total Liabilities 3.39b

Total Rating: 4.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.15

1. Piotroski 9.0pt = 4.0

2. FCF Yield 3.52% = 1.76

3. FCF Margin 16.86% = 4.21

4. Debt/Equity 0.29 = 2.46

5. Debt/Ebitda 1.19 = 1.49

6. ROIC - WACC (= 1.19)% = 1.48

7. RoE 10.21% = 0.85

8. Rev. Trend 63.72% = 4.78

9. EPS Trend 62.30% = 3.11

What is the price of STE shares?

As of November 18, 2025, the stock is trading at USD 257.01 with a total of 532,900 shares traded.
Over the past week, the price has changed by -2.65%, over one month by +6.99%, over three months by +5.36% and over the past year by +19.60%.

Is STE a buy, sell or hold?

STERIS has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold STE.

Strong Buy: 3
Buy: 2
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the STE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	281.6	9.6%
Analysts Target Price	281.6	9.6%
ValueRay Target Price	286.4	11.5%

STE Fundamental Data Overview November 15, 2025

Market Cap USD = 25.56b (25.56b USD * 1.0 USD.USD)
P/E Trailing = 37.3659
P/E Forward = 26.2467
P/S = 4.4826
P/B = 3.7526
P/EG = 2.0036
Beta = 1.026
Revenue TTM = 5.70b USD
EBIT TTM = 978.1m USD
EBITDA TTM = 1.47b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 35.3m USD (from shortTermDebt, last quarter)
Debt = 2.06b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.74b USD (from netDebt column, last quarter)
Enterprise Value = 27.30b USD (25.56b + Debt 2.06b - CCE 319.2m)
Interest Coverage Ratio = 14.60 (Ebit TTM 978.1m / Interest Expense TTM 67.0m)
FCF Yield = 3.52% (FCF TTM 961.2m / Enterprise Value 27.30b)
FCF Margin = 16.86% (FCF TTM 961.2m / Revenue TTM 5.70b)
Net Margin = 12.07% (Net Income TTM 688.5m / Revenue TTM 5.70b)
Gross Margin = 44.29% ((Revenue TTM 5.70b - Cost of Revenue TTM 3.18b) / Revenue TTM)
Gross Margin QoQ = 44.23% (prev 45.14%)
Tobins Q-Ratio = 2.62 (Enterprise Value 27.30b / Total Assets 10.41b)
Interest Expense / Debt = 0.72% (Interest Expense 14.9m / Debt 2.06b)
Taxrate = 23.94% (60.6m / 253.1m)
NOPAT = 743.9m (EBIT 978.1m * (1 - 23.94%))
Current Ratio = 2.37 (Total Current Assets 2.11b / Total Current Liabilities 888.9m)
Debt / Equity = 0.29 (Debt 2.06b / totalStockholderEquity, last quarter 7.01b)
Debt / EBITDA = 1.19 (Net Debt 1.74b / EBITDA 1.47b)
Debt / FCF = 1.81 (Net Debt 1.74b / FCF TTM 961.2m)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.61% (Net Income 688.5m / Total Assets 10.41b)
RoE = 10.21% (Net Income TTM 688.5m / Total Stockholder Equity 6.75b)
RoCE = 11.32% (EBIT 978.1m / Capital Employed (Equity 6.75b + L.T.Debt 1.90b))
RoIC = 8.50% (NOPAT 743.9m / Invested Capital 8.75b)
WACC = 7.32% (E(25.56b)/V(27.62b) * Re(7.86%) + D(2.06b)/V(27.62b) * Rd(0.72%) * (1-Tc(0.24)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈848.8m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 309.6 (DCF Value 30.38b / Shares Outstanding 98.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 62.30 | EPS CAGR: 7.59% | SUE: 1.35 | # QB: 3
Revenue Correlation: 63.72 | Revenue CAGR: 6.88% | SUE: 0.26 | # QB: 0

Additional Sources for STE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle